WINT
NASDAQWindtree Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.10+0.00 (+0.00%)
2026-02-272026-06-02
News · 26 weeks30%
2025-12-072026-05-31
Mix190d
- Other1(100%)
Latest news
25 items- SECSEC Form NT 10-K filed by Windtree Therapeutics Inc.NT 10-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECWindtree Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- PRWindtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesSeismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues) Windtree would receive a payment of $700,000 from Seismic Pharmaceutical Holdings contingent on a financing round resulting in gross cash proceeds of at least $10,000,000 Additionally, Windtree transfers certain cardiovascular development payables to Seismic Pharmaceutical Holdings WARRINGTON, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (OTCID: WINT), a diversified company with several divisions and focused on becoming
- PRWindtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech SpaceWindtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans are originated CommLoan has streamlined the process of obtaining commercial real estate financing WARRINGTON, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that it has signed a letter of intent to acquire CommLoan, Inc., a commercial tech finance company. CommLoan will retain key employees and become a subsidiary of
- SECWindtree Therapeutics Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECSEC Form 424B3 filed by Windtree Therapeutics Inc.424B3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECSEC Form 10-Q filed by Windtree Therapeutics Inc.10-Q - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- PRWindtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the LicenseeThe Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed treatments include SURFAXIN®, lyophilized lucinactant and AEROSURF® (a drug and device combination) The franchise is intended to treat premature infants with respiratory distress syndrome (RDS) Windtree will communicate more information about milestone payments it may receive from its licensing partner and the future timing of those potential payments WARRINGTON, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (OTCID: WINT), a diver
- SECSEC Form NT 10-Q filed by Windtree Therapeutics Inc.NT 10-Q - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- PRWindtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent EstateWindtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute heart failure in Canada and Mexico The pure SERCA2a activators patent for acute heart failure was granted in Isreal WARRINGTON, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that acute heart failure patents are allowed in Canada (Patent Application No. 3,130,261) and Mexico (Patent Application No. MX/a/2021/010483). Additi
- PRWindtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services CompanyWindtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree to acquire Titan Environmental Services, Inc. The executed agreement releases the parties from their reciprocal surviving obligations WARRINGTON, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that it has signed a letter of intent with TESI (OTC:TESI), an environmental services company, and Windtree will receive $7.5 mil
- SECSEC Form 424B3 filed by Windtree Therapeutics Inc.424B3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECSEC Form S-1 filed by Windtree Therapeutics Inc.S-1 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECWindtree Therapeutics Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECWindtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECWindtree Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECWindtree Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- PRWindtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder MeetingThe Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders The stockholder approved proposals provide the foundation for Windtree revenue generating deals in environmental services Windtree is choosing to focus on environmental services and other revenue generating businesses – the Company will not move forward with the cryptocurrency treasury strategy Company continues to move forward with potential deals for both biotech assets that will bring in near term cash and long term milestones and royalties WARRINGTON, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Compan
- SECWindtree Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECSEC Form 10-Q filed by Windtree Therapeutics Inc.10-Q - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECSEC Form NT 10-Q filed by Windtree Therapeutics Inc.NT 10-Q - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- PRWindtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30% Istaroxime interim data was consistent with the profile seen in previous studies gives Windtree confidence to move forward with a global Phase 3 study WARRINGTON, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the Company is actively seeking long-term development partners, announced that
- SECSEC Form DEF 14A filed by Windtree Therapeutics Inc.DEF 14A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- SECWindtree Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)
- INSIDERSEC Form 3 filed by new insider Kucharchuk Andrew Albert3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)
WINT FAQ
5 questionsWhat does Windtree Therapeutics Inc. do?
Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for...Where does WINT stock trade?
Windtree Therapeutics Inc. (WINT) is listed on NASDAQ.What sector and industry is WINT in?
Windtree Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to WINT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare WINT side-by-side with any of them on Quantisnow.How can I track WINT on Quantisnow?
Quantisnow aggregates Windtree Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WINT to receive live email and push alerts on every new disclosure.